Article (Scientific journals)
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.
Nabergoj, Mitja; Mauff, Katya; Beelen, Dietrich et al.
2022In Bone Marrow Transplantation, 57, p. 1072 - 1078
Peer Reviewed verified by ORBi
 

Files


Full Text
478.pdf
Publisher postprint (981.04 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Female; Humans; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Breast Neoplasms/therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation/adverse effects; Leukemia, Myeloid, Acute/therapy; Myeloproliferative Disorders; Breast Neoplasms; Hematopoietic Stem Cell Transplantation; Leukemia, Myeloid, Acute; Hematology; Transplantation
Abstract :
[en] We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.
Disciplines :
Hematology
Author, co-author :
Nabergoj, Mitja ;  Hematology Service, Institut Central des Hôpitaux (ICH), Hôpital du Valais, Sion, Switzerland. mitja.nabergoj@hopitalvs.ch
Mauff, Katya;  EBMT Statistical Unit, Leiden, the Netherlands
Beelen, Dietrich;  Department of Bone Marrow Transplantation, Universitätsklinikum Essen, Essen, Germany
Ganser, Arnold;  Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
Kröger, Nicolaus ;  University Hospital Eppendorf, Hamburg, Germany
Stölzel, Friedrich;  Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany
Finke, Jürgen ;  Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany
Passweg, Jakob;  University Hospital, Basel, Switzerland
Cornelissen, Jan;  Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
Schub, Natalie;  Division for Stem Cell Transplantation and Immunotherapy, University Hospital of Schleswig-Holstein, Kiel, Germany
Veelken, Joan Hendrik ;  Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Wilson, Keith;  Department of Hematology, University Hospital of Wales, Heath Park, Cardiff, Wales, UK
Zuckerman, Tsila ;  Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
Hunault-Berger, Mathilde ;  CHRU Angers, Angers, France
Lioure, Bruno;  Department of Hematology, ICANS, Strasbourg, France
Porras, Rocio Parody;  Deparment of Clinical Hematalogy, ICO-Hospital Duran i Reynals, Barcelona, Spain
Turlure, Pascal;  Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire, Limoges, France
Kerre, Tessa;  Department of Hematology, Ghent University Hospital, Ghent, Belgium
Koster, Linda;  EBMT Date Office, Leiden, the Netherlands
Hayden, Patrick J;  Department of Hematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
Onida, Francesco ;  Hematology-BMT Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milan, Italy
Scheid, Christof;  University Hospital Koeln, Cologne, Germany
Chalandon, Yves ;  Division of Hematology, Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland
Robin, Marie ;  Hôpital Saint-Louis, APHP, Université Paris 7, Paris, France
Yakoub-Agha, Ibrahim ;  CHU de Lille, Univ Lille, INSERM U1286, INFINITE, 59000, Lille, France. ibrahim.yakoubagha@chru-lille.fr
More authors (16 more) Less
Language :
English
Title :
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.
Publication date :
July 2022
Journal title :
Bone Marrow Transplantation
ISSN :
0268-3369
eISSN :
1476-5365
Publisher :
Springer Nature, England
Volume :
57
Pages :
1072 - 1078
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
Funding for this study was indirectly provided by support of the CMWP of the EBMT.
Available on ORBi :
since 30 December 2022

Statistics


Number of views
89 (1 by ULiège)
Number of downloads
75 (0 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
1
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi